Katie Drumond: Right. Move fast and break everything as we have said a lot at Wired in the past few months. We will take a short break, when we come back, what you need to read on Wired today.
Welcome back Strange valley. I am Katie Drumond, Global Editor of Wired. I was involved by the business and industry director of Wired, Zoë Schiffer. Now Zoë, before I let you go, tell our listeners what they absolutely have to read, have to read on wired.com today, in addition to the stories we have said in this episode.
Zoë Schiffer: ALRIGHT. I wish I had a good, happy, sublime story to talk to you, but I had another resignation and gloomy story, and that was because of
Katie Drumond: AW-Shucks.
Zoë Schiffer: I know. It was by Caroline Haskins, a freely working person for us, and we actually announced she joined the desk. It is interesting. She was amazing. She is very good. I am very excited. And she wrote a work that we published yesterday on how to cut Trump and Elon Musk at the FDA, so another government experienced a serious budget and the reduction of personnel has caused drug development. And she received this from dozens of sec documents from pharmaceutical companies.
Katie Drumond: So, between SEC's records and what you and Emily reported yesterday on these credit card freezing cases, it seems that we are seeing the federal agencies stop here in some really consequences.
Zoë Schiffer: Yes. I mean, it is interesting because pharmaceutical companies, pharmaceutical companies do not even say, “the FDA does not approve our medicine, and so these drugs cannot appear on the market.” They said that this agency was very slow to move according to the design because the shares were very, very high when you talk about medicine and medicine. And so the cutting of personnel and budget cuts. The worry is that this will be delayed. And if you are a pharmaceutical company that determines between continuing to produce a approved drug or put a lot of time, energy and resources, the money behind the development of a new drug that you are not sure will receive the approval of the FDA, suddenly you will see less and many of them, we will pour money into the existing product pipe. And that is really serious for those who may need these new therapies.
Katie Drumond: Zoë, thank you for all the joy that you have brought to our program today. Thank you for joining me. Although actually, the fascinating and grateful things for your report and the group's report.
Zoë Schiffer: Thank you very much for having me.
Katie Drumond: That is our program for today. We will associate with all the stories we have said today in the program notes. Make sure to see the fifth episode of Strange valleyIt is all about the movement to support the celebrity of Silicon Valley. If you like what you've heard today, make sure to track our program and evaluate it on your Podcast app. If you want to contact any of us for questions, comments or displaying suggestions, please write to us at Unnannyvalley@wired.com.
Amar Lal at Macro Sound mixes this episode. Jake Lummus is our studio engineer. Jordan Bell is our executive manufacturer, the leader of Condé Nast's global audio, Chris Bannon. And I'm Katie Drumond, Wired's global editor.
Goodbye.